* requires high-flow oxygen supplementation * current or imminent respiratory failure * has rapidly progressing symptoms that in the investigator's opinion are likely to progress to needing high-flow oxygen or to respiratory failure within 24 to 48 hours * any condition which, in the investigator's opinion, participation would not be in the subject's best interest or could prevent, limit, or confound the protocol-specified assessments * has participated, or is participating in, a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies against sars-cov-2, or intravenous immunoglobulin within 3 months or less than 5 half-lives of the investigational product (whichever is longer) * pregnant or lactating and breast feeding, or planning on either during the study * unable to comply with planned study procedures and be available for all follow-up visits

* requires high-flow oxygen supplementation * current or imminent respiratory failure * has rapidly progressing symptoms that in the investigator's opinion are likely to progress to needing high-flow oxygen or to respiratory failure within 24 to 48 hours * any condition which, in the investigator's opinion, participation would not be in the subject's best interest or could prevent, limit, or confound the protocol-specified assessments * has participated, or is participating in, a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies against sars-cov-2, or intravenous immunoglobulin within 3 months or less than 5 half-lives of the investigational product (whichever is longer) * pregnant or lactating and breast feeding, or planning on either during the study * unable to comply with planned study procedures and be available for all follow-up visits

- requires high-flow oxygen supplementation - current or imminent respiratory failure - has rapidly progressing symptoms that in the investigator's opinion are likely to progress to needing high-flow oxygen or to respiratory failure within 24 to 48 hours - any condition which, in the investigator's opinion, participation would not be in the subject's best interest or could prevent, limit, or confound the protocol-specified assessments - has participated, or is participating in, a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies against sars-cov-2, or intravenous immunoglobulin within 3 months or less than 5 half-lives of the investigational product (whichever is longer) - pregnant or lactating and breast feeding, or planning on either during the study - unable to comply with planned study procedures and be available for all follow-up visits

- requires high-flow oxygen supplementation - current or imminent respiratory failure - has rapidly progressing symptoms that in the investigator's opinion are likely to progress to needing high-flow oxygen or to respiratory failure within 24 to 48 hours - any condition which, in the investigator's opinion, participation would not be in the subject's best interest or could prevent, limit, or confound the protocol-specified assessments - has participated, or is participating in, a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies against sars-cov-2, or intravenous immunoglobulin within 3 months or less than 5 half-lives of the investigational product (whichever is longer) - pregnant or lactating and breast feeding, or planning on either during the study - unable to comply with planned study procedures and be available for all follow-up visits